162 related articles for article (PubMed ID: 24023782)
21. Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer.
Benard A; Goossens-Beumer IJ; van Hoesel AQ; de Graaf W; Horati H; Putter H; Zeestraten EC; van de Velde CJ; Kuppen PJ
BMC Cancer; 2014 Jul; 14():531. PubMed ID: 25047223
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
[TBL] [Abstract][Full Text] [Related]
23. A robust gene signature for the prediction of early relapse in stage I-III colon cancer.
Dai W; Li Y; Mo S; Feng Y; Zhang L; Xu Y; Li Q; Cai G
Mol Oncol; 2018 Apr; 12(4):463-475. PubMed ID: 29377588
[TBL] [Abstract][Full Text] [Related]
24. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
25. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer.
Poincloux L; Durando X; Seitz JF; Thivat E; Bardou VJ; Giovannini MH; Parriaux D; Barriere N; Giovannini M; Delpero JR; Monges G
Surg Oncol; 2009 Dec; 18(4):357-65. PubMed ID: 19027288
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic values of the clinical, morphological and molecular biological characteristics of colon adenocarcinoma].
Raskin GA; Pozharissky KM; Orlova RV; Petrov SV
Arkh Patol; 2015; 77(5):26-30. PubMed ID: 26978017
[TBL] [Abstract][Full Text] [Related]
27. Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.
Sperlich A; Balmert A; Doll D; Bauer S; Franke F; Keller G; Wilhelm D; Mur A; Respondek M; Friess H; Nitsche U; Janssen KP
BMC Cancer; 2018 Oct; 18(1):998. PubMed ID: 30340556
[TBL] [Abstract][Full Text] [Related]
28. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
29. Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer.
Chida S; Okayama H; Noda M; Saito K; Nakajima T; Aoto K; Hayase S; Momma T; Ohki S; Kono K; Takenoshita S
Carcinogenesis; 2016 Sep; 37(9):878-887. PubMed ID: 27287872
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
31. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
[TBL] [Abstract][Full Text] [Related]
32. Comparison of EpCAM
Liu M; Di J; Liu Y; Su Z; Jiang B; Wang Z; Su X
Cancer Biol Ther; 2018; 19(10):939-947. PubMed ID: 29580161
[TBL] [Abstract][Full Text] [Related]
33. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
Bohanes P; Yang D; Loupakis F; LaBonte MJ; Gerger A; Ning Y; Lenz C; Lenz F; Wakatsuki T; Zhang W; Benhaim L; El-Khoueiry A; El-Khoueiry R; Lenz HJ
Pharmacogenomics J; 2015 Jun; 15(3):226-34. PubMed ID: 25487679
[TBL] [Abstract][Full Text] [Related]
34. KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.
Ribeiro KB; da Silva Zanetti J; Ribeiro-Silva A; Rapatoni L; de Oliveira HF; da Cunha Tirapelli DP; Garcia SB; Feres O; da Rocha JJ; Peria FM
Cancer Biomark; 2016 Mar; 16(4):513-21. PubMed ID: 27062566
[TBL] [Abstract][Full Text] [Related]
35. Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen.
Liu C; Dong B; Lu A; Qu L; Xing X; Meng L; Wu J; Eric Shi Y; Shou C
BMC Cancer; 2010 Jul; 10():359. PubMed ID: 20604972
[TBL] [Abstract][Full Text] [Related]
36. S100B protein expressions as an independent predictor of early relapse in UICC stages II and III colon cancer patients after curative resection.
Hwang CC; Chai HT; Chen HW; Tsai HL; Lu CY; Yu FJ; Huang MY; Wang JY
Ann Surg Oncol; 2011 Jan; 18(1):139-45. PubMed ID: 20628824
[TBL] [Abstract][Full Text] [Related]
37. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
38. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
[TBL] [Abstract][Full Text] [Related]
39. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse.
Lu CY; Uen YH; Tsai HL; Chuang SC; Hou MF; Wu DC; Juo SH; Lin SR; Wang JY
Br J Cancer; 2011 Mar; 104(7):1178-84. PubMed ID: 21343933
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of p53 messenger ribonucleic acid expression in patients after curative resection for stage I to III colorectal cancer: association with colon cancer stem cell markers.
Huh JW; Kim HR; Kim YJ
J Am Coll Surg; 2013 Jun; 216(6):1063-9. PubMed ID: 23571142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]